Literature DB >> 23592661

Peroxisome proliferator-activated receptor delta protects against obesity-related glomerulopathy through the P38 MAPK pathway.

Zhencheng Yan1, Yinxing Ni, Peijian Wang, Jian Chen, Hongbo He, Jing Sun, Tingbing Cao, Jing Chen, Zhigang Zhao, Zhidan Luo, Lin Chen, Daoyan Liu, Zhiming Zhu.   

Abstract

OBJECTIVE: Obesity is a prominent component of metabolic syndrome and a major risk factor for renal disease. The aim of this study was to explore the effect of cross-talk between peroxisome proliferator-activated receptor (PPAR)δ and p38 mitogen-activated protein kinase (p38 MAPK) on obesity-related glomerulopathy. DESIGN AND METHODS: Male Wistar rats were randomly assigned to standard laboratory chow or a high-fat diet for 32 weeks. Glomerular mesangial cells HBZY-1 and mature differentiation 3T3-L1 cells were cocultured and were transfected with PPARδ-expressing vectors or treated with agonist or inhibitor of PPARδ or p38 MAPK.
RESULTS: Rats on a high-fat diet showed typical characteristics of metabolic syndrome including obesity, dyslipidemia, insulin resistance, and hypertension. Rats on a high-fat diet also had significant glomerular hypertrophy and extracellular matrix accumulation, which were accompanied by increased p38 MAPK phosphorylation and decreased PPARδ expression in the kidney tissue. The roles of p38 MAPK and PPARδ in a coculture system of mesangial cells and mature differentiation 3T3-L1 cells were further explored. PPARδ suppression promoted laminin and type IV collagen secretion through p38 MAPK phosphorylation in mesangial cells, whereas PPARδ overexpression or PPARδ agonist attenuated phosphorylation of p38 MAPK and laminin and type IV collagen secretion.
CONCLUSIONS: The characteristics of obesity-related glomerulopathy, which might be partly caused by PPARδ suppression-induced p38 MAPK activation and laminin and type IV collagen secretion was demonstrated.
Copyright © 2013 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23592661     DOI: 10.1002/oby.20103

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  6 in total

Review 1.  Impact of obesity as an independent risk factor for the development of renal injury: implications from rat models of obesity.

Authors:  Kasi C McPherson; Corbin A Shields; Bibek Poudel; Brianca Fizer; Alyssa Pennington; Ashley Szabo-Johnson; Willie L Thompson; Denise C Cornelius; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-12

2.  WNT/β-catenin signaling regulates cigarette smoke-induced airway inflammation via the PPARδ/p38 pathway.

Authors:  Lingli Guo; Tao Wang; Yanqiu Wu; Zhicheng Yuan; Jiajia Dong; Xiao'ou Li; Jing An; Zenglin Liao; Xue Zhang; Dan Xu; Fu-Qiang Wen
Journal:  Lab Invest       Date:  2015-08-31       Impact factor: 5.662

3.  Zinc delays the progression of obesity-related glomerulopathy in mice via down-regulating P38 MAPK-mediated inflammation.

Authors:  Manyu Luo; Ping Luo; Zhiguo Zhang; Kristen Payne; Sara Watson; Hao Wu; Yi Tan; Yushuang Ding; Weixia Sun; Xinmin Yin; Xiang Zhang; Gilbert Liu; Kupper Wintergerst; Lining Miao; Lu Cai
Journal:  Obesity (Silver Spring)       Date:  2016-03-29       Impact factor: 5.002

Review 4.  PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension.

Authors:  Yanli Jiang; Qiang Li; Mengxiao Jia; Zhencheng Yan
Journal:  Int J Hypertens       Date:  2019-04-03       Impact factor: 2.420

5.  Emodin Attenuated the Kidney Damage of High-Fat-Diet Mice via the Upregulation of Glucagon-Like Peptide-1 Receptor.

Authors:  Jinlei Liu; Yao Sun; Hongwei Zheng; Jing Wang; Lili Liu; Bing Song; Haoqiang Zhang
Journal:  Biomed Res Int       Date:  2021-05-31       Impact factor: 3.411

Review 6.  The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy.

Authors:  Shudong Wang; Lijuan Ding; Honglei Ji; Zheng Xu; Quan Liu; Yang Zheng
Journal:  Int J Mol Sci       Date:  2016-06-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.